{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:37:52Z","timestamp":1794962272436,"version":"4.9.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In all 1597 patients, the use of\u00a0haploidentical donors increased from 3% in 2013 to 19% in 2019. In study-eligible 1032 patients who received peripheral blood grafts for chronic-phase myelofibrosis, 38% of recipients of haploidentical HCT were non-White\/Caucasian. Matched sibling donor (MSD)\u2013HCTs were associated with superior overall survival (OS) in the first 3\u00a0months (haploidentical hazard ratio [HR], 5.80 [95% confidence interval (CI), 2.52-13.35]; matched unrelated (MUD) HR, 4.50 [95%\u00a0CI, 2.24-9.03]; mismatched unrelated HR, 5.13 [95%\u00a0CI, 1.44-18.31]; P\u00a0&amp;lt; .001). This difference in OS aligns with lower graft failure with MSD (haploidentical HR, 6.11 [95%\u00a0CI, 2.98-12.54]; matched unrelated HR, 2.33 [95%\u00a0CI, 1.20-4.51]; mismatched unrelated HR, 1.82 [95%\u00a0CI, 0.58-5.72]). There was no significant difference in OS among haploidentical, MUD, and mismatched unrelated donor HCTs in the first 3\u00a0months. Donor type was not associated with differences in OS beyond 3\u00a0months after HCT, relapse, disease-free survival, or OS among patients who underwent HCT within 24\u00a0months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. Although MSD-HCTs were superior, there is no significant difference in HCT outcomes from haploidentical and MUDs. These results establish haploidentical HCT with posttransplantation cyclophosphamide as a viable option\u00a0in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013451","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:14:16Z","timestamp":1719328456000},"page":"4281-4293","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Donor types and outcomes of transplantation in myelofibrosis: a\u00a0CIBMTR study"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"first","affiliation":[{"name":"1Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Estrada-Merly","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-3682","authenticated-orcid":false,"given":"M. Queralt","family":"Salas","sequence":"additional","affiliation":[{"name":"3Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0575","authenticated-orcid":false,"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"DeVos","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-5730","authenticated-orcid":false,"given":"Xi","family":"Fang","sequence":"additional","affiliation":[{"name":"4Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-5699","authenticated-orcid":false,"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[{"name":"5Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Andrade-Campos","sequence":"additional","affiliation":[{"name":"6Hospital del Mar Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[{"name":"7Department of Bone Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Agrawal","sequence":"additional","affiliation":[{"name":"8Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"9Oncology Center, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL"},{"name":"13Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology, University of Virginia Health System, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"15Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[{"name":"16The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[{"name":"17The Ottawa Hospital Transplantation and Cellular Therapy Program and Ottawa Hospital Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"18Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"19Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosha","family":"Farhadfar","sequence":"additional","affiliation":[{"name":"20Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-7442","authenticated-orcid":false,"given":"Shatha","family":"Farhan","sequence":"additional","affiliation":[{"name":"21Henry Ford Health System Stem Cell Transplant & Cellular Therapy Program, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita P.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"22Division of Hematology\/Medical Oncology, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"23Houston Methodist Hospital and Neal Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[{"name":"24Division of Hematological Malignancies, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[{"name":"25Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-1450","authenticated-orcid":false,"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[{"name":"26Department of Hematology, St. Vincent's Hospital Sydney, Australia"},{"name":"27School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia"},{"name":"28School of Medicine, University of Notre Dame, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-6539","authenticated-orcid":false,"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"29Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"30Department of BMT & Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"31University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-5678","authenticated-orcid":false,"given":"Mark","family":"Juckett","sequence":"additional","affiliation":[{"name":"32Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-480X","authenticated-orcid":false,"given":"Maxwell M.","family":"Krem","sequence":"additional","affiliation":[{"name":"33Kansas City VA Medical Center, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh P.","family":"Lad","sequence":"additional","affiliation":[{"name":"34Leukemia\/Bone Marrow Transplant Program of British Columbia, Division of Hematology, Department of Medicine, The University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Liesveld","sequence":"additional","affiliation":[{"name":"35Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"36City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1581-3445","authenticated-orcid":false,"given":"Adriana K.","family":"Malone","sequence":"additional","affiliation":[{"name":"37The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ort\u00ed","sequence":"additional","affiliation":[{"name":"38Department of Hematology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3615","authenticated-orcid":false,"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[{"name":"39Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaphol","family":"Pawarode","sequence":"additional","affiliation":[{"name":"40Adult Blood and Marrow Transplantation and Cellular Therapy, Rogel Cancer Center, Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"41Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"42Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van der Poel","sequence":"additional","affiliation":[{"name":"43Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6092-1536","authenticated-orcid":false,"given":"Olle","family":"Ringden","sequence":"additional","affiliation":[{"name":"44Translational Cell Therapy Group, Clinical Science, Intervention, and Technology Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"45Novant Health Cancer Institute, Winston Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4753","authenticated-orcid":false,"given":"Alicia","family":"Rov\u00f3","sequence":"additional","affiliation":[{"name":"46Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"47Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0301-5139","authenticated-orcid":false,"given":"Mary Lynn","family":"Savoie","sequence":"additional","affiliation":[{"name":"48University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4308-2152","authenticated-orcid":false,"given":"Sachiko","family":"Seo","sequence":"additional","affiliation":[{"name":"49Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"50Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"51Division of Hematology, Oncology, and Cell Therapy, RUSH University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-1007","authenticated-orcid":false,"given":"Leo F.","family":"Verdonck","sequence":"additional","affiliation":[{"name":"52Department of Hematology\/Oncology, Isala Clinic, Zwolle, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"53Division of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldeep","family":"Wirk","sequence":"additional","affiliation":[{"name":"54Virginia Commonwealth University, Massey Comprehensive Cancer Center, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[{"name":"7Department of Bone Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"1Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"55Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"},{"name":"56Department of Oncologic Sciences, Morsani College of Medicine, University South of Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"57Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"36City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7839","authenticated-orcid":false,"given":"Bart","family":"Scott","sequence":"additional","affiliation":[{"name":"58Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"5Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"22","key":"2024082713060973300_bib1","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2024082713060973300_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024082713060973300_bib3","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1182\/blood-2022-157735","article-title":"Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: durability of response and safety beyond week 24 in the phase 2 MANIFEST Study","volume":"140","author":"Harrison","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2024082713060973300_bib4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10373","key":"2024082713060973300_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"2024082713060973300_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.hoc.2020.12.008","article-title":"Accelerated and blast phase myeloproliferative neoplasms","volume":"35","author":"Jain","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"2024082713060973300_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2024082713060973300_bib8","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024082713060973300_bib9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2024082713060973300_bib10","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024082713060973300_bib11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2024082713060973300_bib12","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3324\/haematol.2022.281958","article-title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"108","author":"Murthy","year":"2023","journal-title":"Haematologica"},{"issue":"15","key":"2024082713060973300_bib13","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/bloodadvances.2023009886","article-title":"A\u00a0simple prognostic system in myelofibrosis patients undergoing allogeneic stem cell transplant: a CIBMTR\/EBMT analysis","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024082713060973300_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024082713060973300_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"issue":"14","key":"2024082713060973300_bib16","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2024082713060973300_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024082713060973300_bib18","doi-asserted-by":"crossref","first-page":"346 e1","DOI":"10.1016\/j.jtct.2023.03.007","article-title":"Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2024082713060973300_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024082713060973300_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","article-title":"Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation","volume":"25","author":"Raj","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024082713060973300_bib21","doi-asserted-by":"crossref","first-page":"49.e1","DOI":"10.1016\/j.jtct.2022.10.015","article-title":"Haploidentical hematopoietic cell transplantation for myelofibrosis in the ruxolitinib era","volume":"29","author":"Gambella","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2024082713060973300_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"2024082713060973300_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024082713060973300_bib24","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/leu.2015.75","article-title":"Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies","volume":"29","author":"Olsson","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2024082713060973300_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2024082713060973300_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00985764","article-title":"Score test of homogeneity for survival data","volume":"1","author":"Commenges","year":"1995","journal-title":"Lifetime Data Anal"},{"issue":"1","key":"2024082713060973300_bib27","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"2024082713060973300_bib28","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","article-title":"Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation","volume":"4","author":"Al Malki","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024082713060973300_bib29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2024082713060973300_bib30","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2022009240","article-title":"Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type","volume":"7","author":"Mehta","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2024082713060973300_bib31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"2024082713060973300_bib32","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/bloodadvances.2019000614","article-title":"HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"3","author":"Meybodi","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"2024082713060973300_bib33","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1001\/jamaoncol.2021.3676","article-title":"Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades: a Blood or Marrow Transplant Survivor Study Report","volume":"7","author":"Bhatia","year":"2021","journal-title":"JAMA Oncol"},{"issue":"25","key":"2024082713060973300_bib34","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024082713060973300_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024082713060973300_bib36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/01.TP.0000129809.09718.7E","article-title":"A\u00a0comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation","volume":"78","author":"Le Blanc","year":"2004","journal-title":"Transplantation"},{"issue":"11","key":"2024082713060973300_bib37","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2024082713060973300_bib38","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/bmt.2015.172","article-title":"Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis","volume":"50","author":"Slot","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"2024082713060973300_bib39","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2024082713060973300_bib40","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN International Working Group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2024082713060973300_bib41","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.bbmt.2017.05.007","article-title":"Allogeneic stem cell transplantation in myelofibrosis","volume":"23","author":"Jain","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024082713060973300_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2024082713060973300_bib43","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kroger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024082713060973300_bib44","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024082713060973300_bib45","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2024082713060973300_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","article-title":"Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors","volume":"8","author":"Guru Murthy","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4281\/2239647\/blooda_adv-2024-013451-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4281\/2239647\/blooda_adv-2024-013451-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:06:42Z","timestamp":1724764002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4281\/516713\/Donor-types-and-outcomes-of-transplantation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":46,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013451","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}